Market Overview

UPDATE: Oppenheimer Raises PT to $89 on Amgen

Share:
Related AMGN
Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Amgen's (AMGN) CEO Bob Bradway on Q1 2018 Results - Earnings Call Transcript (Seeking Alpha)

Oppenheimer reiterated its Perform rating on Amgen (NASDAQ: AMGN) and increased its price target from $85 to $89.

Oppenheimer commented, "Amgen's 3Q revenues and EPS topped both our estimate and the Street consensus. In addition, Amgen again raised its 2012 revenue and EPS guidance. We highlight weakness in Aranesp and NEUPOGEN were more than offset by growth led by Enbrel, Xgeva, Sensipar and Nplate. Overall Amgen is demonstrating leverage in the model and continues to guide to revenue growth in excess of expense increases. Amgen remains our top pick for 4Q based on anticipated dividend increase of ~30%. We also believe that data from four Phase II studies of AMG 145 at AHA in Nov-'12 could be a significant catalyst. We maintain our Perform rating based on valuation and are increasing our PT to $89/share based on comps analysis."

Amgen closed at $87.32 on Tuesday.

Latest Ratings for AMGN

DateFirmActionFromTo
Apr 2018BarclaysMaintainsEqual-WeightEqual-Weight
Feb 2018Atlantic EquitiesDowngradesOverweightNeutral
Feb 2018Credit SuisseMaintainsNeutralNeutral

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (AMGN)

View Comments and Join the Discussion!